On October 21, 2026, the U.S. District Court for the District of Massachusetts partially granted a motion for summary judgment in favor of an orthopedic medical device company whose payment of commissions to independent contractor (IC) sales representatives led to a lawsuit alleging violations of the Anti-Kickback Statute (AKS).

In United States ex rel. Langer v. Zimmer Biomet Holdings Inc., No. 21-cv-11293-PBS (D. Mass. Oct. 21, 2026), Judge Patti B. Saris declined to adopt a broad interpretation of the AKS under which commission-based payments would automatically be considered remuneration paid with the unlawful intent to induce referrals, and rejected False Claims Act (FCA) claims based on a false certification theory.

The court concluded, however, that the relator offered sufficient evidence of suspect actions by the company’s IC sales representatives to allow the case to proceed, on the theory that the company paid the commissions with the unlawful intent to induce referrals under the AKS. The court looked not to a sweeping rule but to factors outlined by the U.S. Department of Health and Human Services Office of Inspector General (HHS-OIG) in an advisory opinion from 1998.[1]

Background

Zimmer Biomet, created by merger in 2015, converted its W-2 sales representatives to 1099 ICs, effective January 1, 2016. They were generally paid on commission, with quotas.

Sales representative Todd Langer, whose employment was terminated after he declined to sign the 1099 agreement, brought an FCA qui tam suit against his former employer in August 2021. Relator Langer alleged that the payment of commissions to IC sales representatives violated the AKS, resulting in fraudulent claims for payment under civil federal and state FCA laws. Neither the United States nor any state intervened in the qui tam suit.

The district court denied the company’s motion to dismiss in 2024, concluding that relator Langer had plausibly alleged that the company’s payments to its IC sales representatives amounted to illegal remuneration with the intent to induce referrals under the AKS and that the company had acted knowingly and willfully. The district court also rejected the company’s argument that dismissal was required pursuant to the FCA’s public disclosure bar.

After discovery, Zimmer Biomet moved for summary judgment on multiple grounds, alleging that (1) no reasonable jury could find that its commission-based payments to its IC sales representatives violated the AKS and (2) even if it could, there was insufficient evidence to prove liability under the FCA.

The Pathways

The district court agreed with the company on the first point and rejected relator Langer’s “broad interpretation of the AKS under which commission-based payments to [IC] sales representatives [automatically] amount to remuneration paid with the unlawful intent to induce referrals.”

In her 55-page opinion, Judge Saris noted that the relator was seeking to hold the company liable under two FCA theories: (1) 31 U.S.C. § 3729(a)(1)(A), which creates liability for any person who “knowingly presents, or causes to be presented, a false or fraudulent claim for payment or approval” to the U.S. government, and (2) 31 U.S.C. § 3729(a)(1)(B), which creates liability for any person who “knowingly makes, uses, or causes to be made or used, a false record or statement material to a false or fraudulent claim.”

Both theories of civil FCA liability were based on an alleged underlying violation of the criminal AKS, 42 U.S.C. § 1320a-7b(b)(2), which prohibits, among other things, the knowing and willful offering or payment of any remuneration (including kickbacks, bribes, or rebates) to induce a person to refer an individual to a person for the furnishing of items or services paid under a federal health care program.

As Judge Saris noted, an AKS-based FCA violation also has two pathways: the first is 42 U.S.C. § 1320a-7b(g), when claims for payment are “resulting from” AKS violations (meaning that the claim would not have been submitted “but for” the illegal kickback; see Epstein Becker Green (EBG) publications on “but-for” causation in the U.S. Court of Appeals for the First Circuit here and here, and the Middle District of Tennessee here). The second pathway is the “false certification” theory: in this context, that the claim is based on a false representation that there is no AKS violation.

The Holding

The First Circuit, Judge Saris noted, has not addressed how the AKS applies to commission-based payments to IC sales representatives. Both relator Langer and the federal government—which participated on this point at oral argument—urged the district court to follow the Fourth Circuit, which has interpreted the AKS to broadly criminalize commissions based on volume or value of sales paid to ICs hired to influence those making health care decisions regarding products or services reimbursable by the federal government.[2] Relator Langer and the government argued that commission-based payments violate the AKS whenever the elements of remuneration, intent to induce referrals, and willfulness are satisfied. 

Yet the district court chose to follow the Fifth, Seventh, and Ninth Circuits, which have focused on a defendant’s intent to improperly influence physicians’ decision-making, not just to increase sales. Indeed, the court was reluctant to “criminalize (with major federal penalties) a standard payment structure for marketing personnel” (quoting United States v. Schena, 142 F.4th 1217 (9th Cir. 2025)) (see EBG blog posts on the Seventh Circuit ruling here and the Ninth Circuit ruling here).

Judge Saris found sufficient evidence of suspect behavior “to present a triable case that Zimmer Biomet paid commissions to its [IC] sales representatives with the unlawful intent to induce referrals required by the AKS.” In so holding, the district court analyzed factors in the HHS-OIG Advisory Opinion 98-10, which asked whether the payment of a sales commission to an independent manufacturers’ representative constitutes grounds for AKS sanctions. Relevant factors, as noted by the district court, included:

  • compensation based on percentage of sales;
  • direct contact with physicians in a position to order items and services paid for by a federal health care program (sales representatives accompanied surgeons to the operating room);
  • attempts to upsell physicians to more expensive products;
  • travel expenses paid for surgeons (the relator flew with surgeons on a private jet owned or chartered by the company); and
  • meals provided to surgeons.

Among the arguments Judge Saris rejected was that (1) there was insufficient evidence to prove a “knowing and willful” AKS violation or an actual false claim made to the government, or (2) as in the case of Omni Healthcare, Inc. v. MD Spine Solutions LLC (another 2025 case decided by Judge Saris; see EBG blog post here), there was no triable case that the payment of commissions was the but-for cause of submitted claims. The court agreed with the company, however, that (1) there was no triable case under a false certification theory, and (2) the company was entitled to summary judgment on all state-law FCA claims except those under Colorado law.

Takeaways

While the AKS contains a “safe harbor” to payments made by employers to employees with a bona fide employment relationship, it does not protect payments to independent contractors. While not binding on the district court, Judge Saris found the HHS-OIG’s Advisory Opinion 98-10 to be a “useful [guidepost] in assessing when a commission-based compensation arrangement with [IC] sales representatives reflects an intent to improperly influence physicians.” As HHS-OIG noted in 1998, “[t]he more factors that are present, the greater the scrutiny we ordinarily will give an arrangement. Of course, in all cases the statute is not violated unless the parties have the requisite intent to induce referrals.”

If you have questions, please reach out to the authors.

Epstein Becker Green Staff Attorney Ann W. Parks contributed to the preparation of this post.

Endnotes

[1] The court also noted OIG Compliance Program Guidance for Pharmaceutical Manufacturers, 68 Fed. Reg. 23731, 23739 (May 5, 2003).

[2] Regarding circuits adopting the broader interpretation, Judge Saris cited the Fourth Circuit cases of United States ex rel. Nicholson v. MedCom Carolinas, Inc., 42 F.4th 185, 194 (4th Cir. 2022), and United States v. Mallory, 988 F.3d 730 (4th Cir. 2021), both involving commissions to independent contractors. The Tenth Circuit has held in the unpublished decision of Joint Technology Inc. v. Weaver, 567 Fed.Appx. 585 (2014), that a contract paying an IC to solicit Medicare and Medicaid referrals for durable medical equipment violated the “Medicare Anti-Kickback Act.”

* * * *

If you have questions, please reach out to the author(s).

The Health Law Advisor blog is currently edited by Emily Chi Fogler.

Back to Health Law Advisor Blog

Search This Blog

Authors

Related Services

Topics

Archives

Jump to Page

Subscribe

Sign up to receive an email notification when new Health Law Advisor posts are published:

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.